GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Impax Laboratories, Inc. (IPXL) [hlAlert]

Rating:
Outperform
IPXL
down 36.66 %

Impax Laboratories, Inc. (IPXL) rated Outperform by Leerink Swann

Posted on: Monday,  Aug 6, 2012  6:56 PM ET by Leerink Swann

Leerink Swann rated Outperform Impax Laboratories, Inc. (NASDAQ: IPXL) on 08/06/2012, when the stock price was $24.00. Since then, Impax Laboratories,
Inc. has lost 36.67% of its value until Leerink Swann rated IPXL Mkt Perform on 03/05/2013, when the price was $15.20.
If you would have followed this Leerink Swann 's recommendation on IPXL, you would have lost 36.66% of your investment in 211 days.

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. In the generic pharmaceuticals market, the Company focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system (CNS), disorders. Its brand-name product portfolio consists of development-stage projects to which it is applying its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceutical Division (Impax Division).

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/5/2013 8:25 AM Hold
None
15.20
as of 12/31/2012
1 Week up  0.44 %
1 Month up  0.73 %
3 Months down  -21.07 %
1 YTD down  -14.62 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/6/2012 6:56 PM Buy
None
24.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy